Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker Oct 17, 2019
Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder Oct 7, 2019
Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019 Sep 25, 2019
Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial Sep 11, 2019
Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder Sep 5, 2019
Adial Pharmaceuticals' Chief Executive Officer to be Featured Live on Cheddar's "Closing Bell" Aug 6, 2019
Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare Jun 19, 2019
Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder Jun 13, 2019
Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization Jun 6, 2019
